[go: up one dir, main page]

WO2004020592A3 - Vaccination genetique retrocanalaire par l'intermediaire des glandes salivaires - Google Patents

Vaccination genetique retrocanalaire par l'intermediaire des glandes salivaires Download PDF

Info

Publication number
WO2004020592A3
WO2004020592A3 PCT/US2003/026872 US0326872W WO2004020592A3 WO 2004020592 A3 WO2004020592 A3 WO 2004020592A3 US 0326872 W US0326872 W US 0326872W WO 2004020592 A3 WO2004020592 A3 WO 2004020592A3
Authority
WO
WIPO (PCT)
Prior art keywords
retroductal
salivary gland
genetic vaccination
methods
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/026872
Other languages
English (en)
Other versions
WO2004020592A2 (fr
Inventor
Sean Tucker
Michael Bennett
Yen-Ju Chen
David Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genteric Inc
Original Assignee
Genteric Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genteric Inc filed Critical Genteric Inc
Priority to AU2003262922A priority Critical patent/AU2003262922A1/en
Publication of WO2004020592A2 publication Critical patent/WO2004020592A2/fr
Publication of WO2004020592A3 publication Critical patent/WO2004020592A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des méthodes pour déclencher une réponse immunitaire, ainsi que des compositions et des méthodes pour transfecter des cellules présentatrices d'antigènes.
PCT/US2003/026872 2002-08-30 2003-08-26 Vaccination genetique retrocanalaire par l'intermediaire des glandes salivaires Ceased WO2004020592A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003262922A AU2003262922A1 (en) 2002-08-30 2003-08-26 Retroductal salivary gland genetic vaccination

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40737502P 2002-08-30 2002-08-30
US60/407,375 2002-08-30
US45399903P 2003-03-11 2003-03-11
US60/453,999 2003-03-11
US63993503A 2003-08-12 2003-08-12
US10/639,935 2003-08-12

Publications (2)

Publication Number Publication Date
WO2004020592A2 WO2004020592A2 (fr) 2004-03-11
WO2004020592A3 true WO2004020592A3 (fr) 2004-08-12

Family

ID=31982347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026872 Ceased WO2004020592A2 (fr) 2002-08-30 2003-08-26 Vaccination genetique retrocanalaire par l'intermediaire des glandes salivaires

Country Status (2)

Country Link
AU (1) AU2003262922A1 (fr)
WO (1) WO2004020592A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034950A1 (fr) 2009-09-16 2011-03-24 Vaxart, Inc. Stratégie d'immunisation pour empêcher une infection par le h1n1
KR102396817B1 (ko) 2014-02-20 2022-05-11 박사르트, 인크. 소장 전달을 위한 제형들
US11433146B2 (en) 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
US6004944A (en) * 1995-03-24 1999-12-21 The Regents Of The University Of California Protein delivery by secretory gland expression
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6004944A (en) * 1995-03-24 1999-12-21 The Regents Of The University Of California Protein delivery by secretory gland expression
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells

Also Published As

Publication number Publication date
AU2003262922A1 (en) 2004-03-19
AU2003262922A8 (en) 2004-03-19
WO2004020592A2 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2002081646A3 (fr) Sequences d'epitopes
WO2004022709A3 (fr) Sequences de sites antigeniques
WO2005037190A3 (fr) Vaccins multiplex
NZ532665A (en) Neisseria meningitidis antigens and compositions
WO2005002621A3 (fr) Methodes visant a eliciter, ameliorer et maintenir des reponses immunitaires dirigees contre des epitopes restreints du cmh de classe i, a des fins prophylactiques ou therapeutiques
WO2004093808A3 (fr) Nouveaux antigenes associes a une tumeur
WO2006017856A3 (fr) Procedes de production de vaccins non antibioresistants
WO2005032582A8 (fr) Compositions immunogènes pour streptococcus pyogenes
WO2003026691A3 (fr) Procede
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
PT1326633E (pt) Composição compreendendo micropartículas imunogénicas
WO2008130382A3 (fr) Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
WO2004005476A3 (fr) Compositions d'acide nucleique destinees a stimuler les reponses immunitaires
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO1999020747A3 (fr) NOUVELLE KINASE HUMAINE POINT DE CONTROLE, hCDS1, COMPOSITIONS ET METHODES ASSOCIEES
WO2004031210A3 (fr) Constructions optimisees a plusieurs epitopes et utilisations de ces dernieres
WO2005000884A8 (fr) Conjugues d'acide poly-gamma-glutamique pour solliciter des reponses immunitaires dirigees contre des bacilles
WO2001074855A3 (fr) Cellule dendritique compositions et methodes pour immunotherapie a base de cellules dendritiques
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003248150A1 (en) Exosome containing exogenous antigen through gene transfection and method for utilizing the same
AU2002242175A1 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
WO2004020592A3 (fr) Vaccination genetique retrocanalaire par l'intermediaire des glandes salivaires
WO2001074845A3 (fr) Peptides immunogenes derives d'antigene d'enveloppe specifique de la prostate (psma) et leur utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP